http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107148574-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-72 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2015-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107148574-B |
| titleOfInvention | hGH assay for guiding the prevention of major adverse cardiac events or cardiovascular disease in a subject |
| abstract | The subject matter of the present invention is a method of determining whether a subject has a vascular risk that can be reduced by a hypotensive therapy with an antihypertensive drug, such as an angiotensin converting enzyme inhibitor (ACE inhibitor), an Angiotensin Receptor Blocker (ARB), β -adrenoceptor blocker (β -blocker) and/or a statin, said method comprising the steps of determining the level of hGH and/or its isoforms in a blood sample of said subject and comparing the determined level of hGH and/or its isoforms in said blood sample with a predetermined threshold, and wherein in case the determined level of hGH and/or its isoforms is above the predetermined threshold, said subject is identified as having a vascular risk that can be reduced by a hypotensive therapy with an antihypertensive drug, such as an angiotensin converting enzyme inhibitor (ACE inhibitor), an Angiotensin Receptor Blocker (ARB), β -adrenoceptor blocker (β -blocker) and/or a statin, and wherein the determined level of hGH and/or its isoforms is below the vascular risk of being reduced by the angiotensin converting enzyme inhibitor (ACE), Angiotensin Receptor Blocker (ARB) and/or statin, e.g. the determination of the angiotensin receptor blocker (β) is not below the angiotensin-inhibitor, angiotensin-blocker (ARB) and/or the statin. |
| priorityDate | 2014-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 714.